Multiple endocrine neoplastic-associated thymic carcinoid tumour in close relatives: octreotide scan as a new diagnostic and follow-up modality. Two case reports.
Thymic carcinoid tumours constitute less than 1% of all carcinoids, and differ markedly from true thymomas in natural history, morphology, prognosis and therapeutic options. New clinical and diagnostic modalities are described in two brothers with thymic carcinoid associated with multiple endocrine neoplasia syndrome. Octreotide scintigraphy proved useful for diagnosis and follow-up, and somatostatin receptor positivity may provide new prospects for treatment of non-resectable or recurrent tumour.
Satta
J
J
Department of Surgery, University of Oulu, Finland.
Ahonen
A
A
Parkkila
S
S
Leinonen
L
L
Apaja-Sarkkinen
M
M
Lepojärvi
M
M
Juvonen
T
T
D002276:Carcinoid Tumor / Q000000981:diagnostic imaging* / Q000235:genetics / Q000601:surgery; D006728:Hormones; D006801:Humans; D007205:Indium Radioisotopes; D008297:Male; D008875:Middle Aged; D018761:Multiple Endocrine Neoplasia Type 1 / Q000000981:diagnostic imaging* / Q000235:genetics / Q000601:surgery; D015282:Octreotide; D004369:Pentetic Acid; D011877:Radionuclide Imaging; D017481:Receptors, Somatostatin; D013004:Somatostatin / Q000031:analogs & derivatives*; D013950:Thymus Gland / Q000000981:diagnostic imaging; D013953:Thymus Neoplasms / Q000000981:diagnostic imaging* / Q000235:genetics / Q000601:surgery; D014057:Tomography, X-Ray Computed
D006728:Hormones; D007205:Indium Radioisotopes; D017481:Receptors, Somatostatin; D013004:Somatostatin; D004369:Pentetic Acid; C081788:pentetreotide; D015282:Octreotide